In short
Systemic sclerosis pulmonary disease is a serious complication that develops when this rare autoimmune condition affects the lungs, leading to breathing difficulties and impacting the length and quality of a person's life.
Key points
- Lung involvement is the leading cause of death in systemic sclerosis, accounting for 20 to 40 percent of mortality in this patient population[8].
- The FDA has approved two medications specifically for systemic sclerosis lung disease: nintedanib in 2019 and tocilizumab in 2021, marking significant advances in treatment options[10].
- Early detection is critical because the greatest risk of developing lung disease occurs in the first few years after systemic sclerosis begins[8].
- Comprehensive care at specialized scleroderma centers that bring together multiple specialists improves outcomes for patients with complex, multiorgan disease[12].
- Clinical trials offer access to potentially promising treatments before they become widely available and contribute valuable knowledge to help future patients[11].
- Pulmonary rehabilitation, oxygen therapy, and symptom management strategies can significantly improve quality of life even when disease cannot be cured[4].
- Family support and caregiver involvement play essential roles in navigating treatment decisions, managing daily challenges, and maintaining emotional well-being[12].
- Despite serious prognosis statistics, individual outcomes vary considerably, and some patients exceed initial predictions through proper treatment and disease management[12].
Understanding the Prognosis
When systemic sclerosis affects the lungs, the outlook becomes more uncertain and concerning. Interstitial lung disease, which is scarring and stiffening of lung tissue, occurs in roughly 35 to 52 percent of people with systemic sclerosis and accounts for 20 to 40 percent of deaths in this patient population. This makes lung involvement one of the leading causes of death for people living with this condition.
The prognosis varies significantly from person to person, depending on several factors. People who have more extensive lung scarring visible on imaging scans, declining lung function measurements, and certain antibody markers in their blood tend to face more challenging outcomes. Those with diffuse cutaneous systemic sclerosis, male gender, African-American race, and the presence of anti-Scl-70 or anti-topoisomerase I antibodies face higher risks of developing and experiencing progression of lung disease.
The severity of lung involvement directly impacts survival expectations. When lung fibrosis progresses, it leads to increasingly difficult breathing, reduced physical capacity, and eventually respiratory failure if not properly managed. The disease can also affect other organs simultaneously, including the heart and kidneys, which further complicates the overall prognosis.
Despite these sobering statistics, early detection and appropriate treatment can make a meaningful difference. The greatest risk of developing interstitial lung disease occurs early in the course of systemic sclerosis, making timely identification particularly important for monitoring disease progression and guiding treatment decisions. Every person's journey with this condition is unique, and some individuals respond better to treatment than others, offering hope even in the face of a challenging diagnosis.
Natural Progression of the Disease
Without treatment, systemic sclerosis pulmonary disease typically follows a progressive course, though the speed and pattern of worsening can vary considerably among individuals. The disease process begins with inflammation in the blood vessels of the lungs, which then triggers a cascade of damaging events. This inflammation causes blood vessel injury, which leads to more inflammation, tissue damage, and the formation of autoantibodies—immune proteins that mistakenly attack the body's own tissues.
As the disease advances untreated, the inflammation and damaged blood vessels result in fibrosis, which is excessive scar tissue formation in the lungs. This scarring makes the lungs stiff and less able to expand and contract properly during breathing. The lungs gradually lose their ability to transfer oxygen into the bloodstream efficiently, leading to progressively worsening shortness of breath.
The natural progression occurs most rapidly in the first few years after systemic sclerosis begins. During this critical window, lung function can decline substantially if the disease goes unrecognized or untreated. People may initially notice only mild breathlessness with exertion, which they might dismiss as being out of shape or getting older. Over time, however, breathing difficulties worsen and begin to interfere with everyday activities like climbing stairs, walking short distances, or even getting dressed.
The extent of lung involvement can vary widely. Some individuals develop only limited areas of scarring that remain relatively stable over time, while others experience extensive fibrosis that continues to progress despite medical intervention. Studies examining lung tissue have found that approximately 21 patients in one cohort had limited systemic sclerosis, suggesting that disease subtype influences how lung involvement develops.
As lung scarring becomes more extensive, the heart must work harder to pump blood through the damaged lung tissue. This can lead to elevated pressure in the lung blood vessels, a condition called pulmonary hypertension. When pulmonary hypertension develops alongside lung fibrosis, the prognosis becomes even more concerning and the burden of symptoms increases substantially.
Possible Complications
People with systemic sclerosis affecting the lungs face numerous potential complications that can develop over time, sometimes unexpectedly. These complications affect not only the respiratory system but can also involve the heart, digestive system, and other organs.
Respiratory infections pose another significant concern for people with scarred lung tissue. The damaged lungs are more vulnerable to bacterial and viral infections, which can trigger sudden worsening of breathing difficulties. Even common respiratory illnesses that healthy individuals recover from easily can cause serious setbacks for those with underlying lung fibrosis.
The digestive system is commonly affected in systemic sclerosis, with most people experiencing problems with heartburn because the muscle connecting the esophagus to the stomach stops working correctly. This allows stomach acid to flow backward into the esophagus. Some patients develop complications in their intestines as well, leading to bloating, excessive gas, abdominal pain and cramping, alternating constipation and diarrhea. In severe cases, people cannot absorb nutrients properly from their digestive tract.
Raynaud's phenomenon, which causes fingers to change color in response to cold or stress, affects nearly everyone with systemic sclerosis. This condition can progress to painful ulcers on the fingertips. When Raynaud's phenomenon becomes severe and uncontrolled, these ulcers can worsen to the point of causing loss of fingertips.
Muscle inflammation, called myositis, may develop and cause weakness and fatigue that further limits physical function. The skin hardening characteristic of systemic sclerosis can restrict joint movement and make it difficult to fully open the mouth. Some people develop red spots on their skin called telangiectasias, which are dilated blood vessels.
Cardiac involvement adds another layer of complexity to the disease. The heart muscle itself can become affected by fibrosis, or the heart may struggle because of increased pressure from pulmonary hypertension. These cardiac complications significantly impact overall health outcomes and require careful monitoring by specialized physicians.
Impact on Daily Life
Living with systemic sclerosis pulmonary disease profoundly affects every aspect of daily existence. The physical limitations imposed by breathing difficulties reshape how people approach even the simplest activities they once took for granted.
Physical activities become increasingly challenging as lung function declines. Tasks that previously required no conscious thought—such as showering, preparing meals, or tidying the home—now demand careful planning and frequent rest breaks. Many people find they need to pace themselves throughout the day, budgeting their limited energy for essential activities. Climbing stairs can become exhausting, and some individuals eventually require supplemental oxygen therapy to maintain adequate oxygen levels in their blood.
The emotional burden of systemic sclerosis lung disease can be as heavy as the physical limitations. Anxiety is common, particularly related to breathing difficulties and uncertainty about disease progression. One patient described experiencing intrusive thoughts and finding the early years after diagnosis especially difficult from an emotional standpoint. The fear of what the future holds—including concerns about declining health, loss of independence, and mortality—weighs heavily on many people's minds.
Social relationships and activities often suffer as the disease progresses. People may feel embarrassed about their breathing difficulties, visible oxygen equipment, or physical limitations, leading them to withdraw from social gatherings and activities they once enjoyed. The unpredictable nature of symptoms can make it difficult to commit to plans in advance, potentially straining friendships and family relationships.
Work life typically requires significant adjustments. Many people find they can no longer perform their previous job duties at the same level, particularly if their work involved physical exertion. Some must reduce their work hours, change careers entirely, or stop working altogether. These employment changes bring not only financial stress but also a sense of lost identity and purpose for many individuals.
Sleep disturbances are common, whether from breathing difficulties, anxiety, medication side effects, or digestive symptoms like heartburn. Poor sleep quality compounds fatigue and makes managing daily activities even more challenging. The need to sleep in certain positions to ease breathing or manage other symptoms can further disrupt rest.
Many people develop strategies to cope with these limitations. Using adaptive equipment, modifying the home environment for easier accessibility, and learning energy conservation techniques can help maintain independence. Pulmonary rehabilitation programs teach breathing exercises and physical conditioning that may improve exercise capacity and quality of life.
Despite these challenges, some individuals find unexpected resilience and perspective. One patient, initially told she had only six months to live, has embraced life and become a strong advocate for others with systemic sclerosis. Her journey demonstrates that while the disease imposes real limitations, it need not define a person's entire existence.
Support for Family Members
Family members play a crucial role in supporting loved ones with systemic sclerosis pulmonary disease, and their understanding of clinical trials and treatment options can significantly benefit the patient's care journey.
Clinical trials represent important opportunities for people with systemic sclerosis lung disease to access potentially promising treatments before they become widely available. Families should understand that clinical trials are research studies designed to test whether new treatments are safe and effective. Not all experimental treatments prove beneficial, but participation in carefully designed trials contributes to medical knowledge that may help future patients.
When a loved one is considering joining a clinical trial, family members can help by researching the study together, attending medical appointments to hear explanations from the research team, and discussing potential benefits and risks. They can ask important questions: What is the purpose of the trial? What treatments or procedures are involved? What are the possible risks and benefits? How long will the trial last? Will the patient need to travel for study visits?
Finding appropriate clinical trials requires systematic effort that family members can assist with. The Pulmonary Fibrosis Foundation and other patient advocacy organizations maintain resources to help locate ongoing studies. Medical specialists treating systemic sclerosis often know about relevant trials at their institutions or can refer patients to centers conducting research.
Preparing for trial participation involves practical support that families can provide. This might include arranging transportation to study visits, helping track symptoms and medication schedules, organizing medical records, and ensuring the patient doesn't miss appointments. Family members can serve as additional sets of eyes and ears during medical discussions, taking notes and helping remember important information shared by the research team.
Beyond clinical trials, families benefit from understanding the broader treatment landscape. Current approved treatments for systemic sclerosis lung disease include medications that slow lung function decline, though neither represents a cure. Treatment decisions depend on multiple factors including the extent of lung involvement, rate of disease progression, presence of other organ complications, and individual patient circumstances.
Emotional support from family members proves invaluable throughout the disease journey. Simply being present, listening without judgment, and acknowledging the challenges the patient faces can provide immense comfort. Family members should also recognize signs that their loved one might benefit from professional mental health support, as anxiety and depression commonly accompany chronic lung disease.
Connecting with specialized scleroderma centers can provide comprehensive care that benefits both patients and families. These centers bring together rheumatologists, pulmonologists, cardiologists, and other specialists experienced in managing the complex aspects of systemic sclerosis. The multidisciplinary approach ensures all disease manifestations receive appropriate attention.
Patient education represents another area where families can make a difference. Learning about systemic sclerosis together, understanding warning signs that should prompt medical attention, and staying informed about new research developments empowers both patients and their support systems. Organizations like the Pulmonary Fibrosis Foundation offer educational resources, webinars, and community support that families can access together.
Registered drugs used for this disease
List of officially registered medicines that are used in the treatment of this condition, based only on the provided sources:
- Nintedanib – An anti-fibrotic tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in September 2019 to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease
- Tocilizumab – An anti-interleukin 6 receptor antagonist approved by the FDA in March 2021 to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease
- Mycophenolate mofetil (MMF) – Immunosuppressive medication studied in scleroderma lung studies in 2006 and 2016, demonstrating benefits for SSc-ILD, though not FDA approved for this specific indication
- Cyclophosphamide (CYC) – Immunosuppressive medication studied in scleroderma lung studies, showing benefits for SSc-ILD, though not FDA approved for this specific indication
